CBD for Tuberous Sclerosis Seizures: Similar Efficacy Did Not Mean Similar Tolerability
In a randomized tuberous-sclerosis trial, both tested CBD regimens reduced seizures more than placebo. The higher assigned dose did not produce a clear additional efficacy advantage and was harder for many patients to tolerate.
A controlled trial in a specific epilepsy population
The study randomized 224 patients with tuberous sclerosis complex and drug-resistant epilepsy to highly purified oral CBD at 25 or 50 mg/kg/day, or placebo, added to existing treatment. A four-week baseline preceded 16 weeks of treatment, including titration.
The outcome was frequency of defined, countable TSC-associated seizures. This is direct clinical evidence in humans, unlike animal seizure experiments or healthy-volunteer brain-stimulation measurements. It still does not establish a treatment effect for every epilepsy type or every cannabis formulation.
Separate the baseline reduction from the placebo comparison
Estimated seizure reductions from baseline were 48.6% at the lower assigned dose, 47.5% at the higher dose and 26.5% with placebo. The model-based reductions relative to placebo were 30.1% and 28.5%, respectively.
These figures describe different comparisons. Reporting a roughly 49% baseline reduction as though placebo patients experienced no improvement would exaggerate the treatment-specific effect. Conversely, the substantial placebo change did not erase the statistically significant primary treatment finding.
Assigned dose was not always achieved dose
At treatment end, 87% of patients assigned 25 mg/kg/day were at that target, compared with 53% assigned 50 mg/kg/day. Thus, the higher-dose arm was not a clean demonstration that every participant continuously received twice the lower dose.
Diarrhea occurred in 31% of the lower-dose group, 56% of the higher-dose group and 25% of placebo recipients. Somnolence showed a similar dose-related pattern. Elevated liver transaminases occurred in 18.9% of CBD-treated patients and in none receiving placebo; concomitant medications, particularly valproate, mattered to the safety interpretation.
What the trial supports
The efficacy signal was evident despite most participants not receiving clobazam, supporting an effect beyond a simple assumption that all benefit came from that interaction. However, multiple concurrent medicines still complicate mechanistic interpretation, and the trial excluded concomitant oral mTOR inhibitors.
The study was not designed to prove formal equivalence between doses. Its findings support weighing benefit against tolerability rather than assuming that a larger dose necessarily improves control. Seizure classification was not confirmed by video-EEG for every event, and longer-term outcomes required further study. None of these dose comparisons should be converted into an unsupervised dosing instruction.
Related analysis: Adult Epilepsy CBD Outcomes: Treatment Retention and Confounding Matter.
Primary research
Elizabeth A. Thiele and colleagues. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. JAMA Neurology (2020). DOI: 10.1001/jamaneurol.2020.4607.
